Lipella Pharmaceuticals Inc. (LIPO)
NASDAQ: LIPO · Real-Time Price · USD
2.401
-0.190 (-7.32%)
Mar 31, 2025, 1:15 PM EDT - Market open

Company Description

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications.

The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD).

Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals logo
Country United States
Founded 2005
IPO Date Dec 20, 2022
Industry Biotechnology
Sector Healthcare
Employees 7
CEO Jonathan Kaufman

Contact Details

Address:
7800 Susquehanna St., Suite 505
Pittsburgh, Pennsylvania 15208
United States
Phone 412-901-0315
Website lipella.com

Stock Details

Ticker Symbol LIPO
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $5.75
CIK Code 0001347242
CUSIP Number 53630L100
ISIN Number US53630L1008
SIC Code 2834

Key Executives

Name Position
Dr. Jonathan Kaufman M.B.A., Ph.D. Co-Founder, Chairman, Chief Executive Officer, President, Secretary and Treasurer
Dr. Michael B. Chancellor M.D. Co-Founder, Chief Medical Officer and Director
Douglas Johnston CPA Chief Financial Officer
Michele Gruber Director of Operations
Katie Johnston Controller

Latest SEC Filings

Date Type Title
Mar 28, 2025 S-3 Registration statement under Securities Act of 1933
Mar 28, 2025 10-K Annual Report
Mar 19, 2025 SCHEDULE 13D/A Filing
Mar 18, 2025 8-K Current Report
Mar 17, 2025 SCHEDULE 13D/A Filing
Mar 11, 2025 SCHEDULE 13D/A Filing
Mar 11, 2025 8-K Current Report
Mar 3, 2025 SCHEDULE 13D/A Filing
Mar 3, 2025 8-K Current Report
Feb 24, 2025 8-K Current Report